Lim E - Search Results

1

The Proliferative and Apoptotic Landscape of Basal-like Breast Cancer.

Alexandrou S, George SM, Ormandy CJ, Lim E, Oakes SR, Caldon CE. Alexandrou S, et al. Among authors: lim e. Int J Mol Sci. 2019 Feb 4;20(3):667. doi: 10.3390/ijms20030667. Int J Mol Sci. 2019. PMID: 30720718 Free PMC article. Review.

2

Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737.

Oakes SR, Vaillant F, Lim E, Lee L, Breslin K, Feleppa F, Deb S, Ritchie ME, Takano E, Ward T, Fox SB, Generali D, Smyth GK, Strasser A, Huang DC, Visvader JE, Lindeman GJ. Oakes SR, et al. Among authors: lim e. Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2766-71. doi: 10.1073/pnas.1104778108. Epub 2011 Jul 18. Proc Natl Acad Sci U S A. 2012. PMID: 21768359 Free PMC article.

3

IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel.

Wee ZN, Yatim SM, Kohlbauer VK, Feng M, Goh JY, Bao Y, Lee PL, Zhang S, Wang PP, Lim E, Tam WL, Cai Y, Ditzel HJ, Hoon DS, Tan EY, Yu Q. Wee ZN, et al. Among authors: lim e. Nat Commun. 2015 Oct 27;6:8746. doi: 10.1038/ncomms9746. Nat Commun. 2015. PMID: 26503059 Free PMC article.

4

The role of MDM2 and MDM4 in breast cancer development and prevention.

Haupt S, Vijayakumaran R, Miranda PJ, Burgess A, Lim E, Haupt Y. Haupt S, et al. Among authors: lim e. J Mol Cell Biol. 2017 Feb 1;9(1):53-61. doi: 10.1093/jmcb/mjx007. J Mol Cell Biol. 2017. PMID: 28096293 Free PMC article. Review.

5

The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy.

Law AM, Lim E, Ormandy CJ, Gallego-Ortega D. Law AM, et al. Among authors: lim e. Endocr Relat Cancer. 2017 Apr;24(4):R123-R144. doi: 10.1530/ERC-16-0404. Epub 2017 Feb 13. Endocr Relat Cancer. 2017. PMID: 28193698 Free PMC article. Review.

6

The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy.

Law AMK, Lim E, Ormandy CJ, Gallego-Ortega D. Law AMK, et al. Among authors: lim e. Endocr Relat Cancer. 2017 Jul;24(7):X1. doi: 10.1530/ERC-16-0404e. Endocr Relat Cancer. 2017. PMID: 28566432 Free PMC article. No abstract available.

7

Emerging data and future directions for CDK4/6 inhibitor treatment of patients with hormone receptor positive HER2-non-amplified metastatic breast cancer.

Lim E, Beith J, Boyle F, de Boer R, Hui R, McCarthy N, Redfern A, Wade T, Woodward N. Lim E, et al. Asia Pac J Clin Oncol. 2018 Oct;14 Suppl 4:12-21. doi: 10.1111/ajco.13065. Asia Pac J Clin Oncol. 2018. PMID: 30288929

8

Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm.

Boyle F, Beith J, Burslem K, de Boer R, Hui R, Lim E, McCarthy N, Redfern A, Woodward N. Boyle F, et al. Among authors: lim e. Asia Pac J Clin Oncol. 2018 Oct;14 Suppl 4:3-11. doi: 10.1111/ajco.13064. Asia Pac J Clin Oncol. 2018. PMID: 30288930

9

Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer.

Portman N, Alexandrou S, Carson E, Wang S, Lim E, Caldon CE. Portman N, et al. Among authors: lim e. Endocr Relat Cancer. 2019 Jan;26(1):R15-R30. doi: 10.1530/ERC-18-0317. Endocr Relat Cancer. 2019. PMID: 30389903 Review.

10

Non-canonical AR activity facilitates endocrine resistance in breast cancer.

Chia K, Milioli H, Portman N, Laven-Law G, Coulson R, Yong A, Segara D, Parker A, Caldon CE, Deng N, Swarbrick A, Tilley WD, Hickey TE, Lim E. Chia K, et al. Among authors: lim e. Endocr Relat Cancer. 2019 Feb 1;26(2):251-264. doi: 10.1530/ERC-18-0333. Endocr Relat Cancer. 2019. PMID: 30557851

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,726 results

Search Page